` HOWL (Werewolf Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

HOWL
vs
S&P 500

Over the past 12 months, HOWL has underperformed S&P 500, delivering a return of -56% compared to the S&P 500's +14% growth.

Stocks Performance
HOWL vs S&P 500

Loading
HOWL
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
HOWL vs S&P 500

Loading
HOWL
S&P 500
Difference
www.alphaspread.com

Performance By Year
HOWL vs S&P 500

Loading
HOWL
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Werewolf Therapeutics Inc vs Peers

S&P 500
HOWL
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Werewolf Therapeutics Inc
Glance View

Market Cap
32.5m USD
Industry
Biotechnology

Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.

HOWL Intrinsic Value
Not Available
Back to Top